A novel cellular RNA helicase, RH116, differentially regulates cell growth, programmed cell death and human immunodeficiency virus type 1 replication.

In an effort to define novel cellular factors regulating human immunodeficiency virus type 1 (HIV-1) replication, a differential display analysis has been performed on endogenously infected cells stimulated with the HIV-suppressive immunomodulator Murabutide. In this study, the cloning and identification of a Murabutide-downregulated gene, named RH116, bearing classical motifs that are characteristic of the DExH family of RNA helicases, are reported. The 116 kDa encoded protein shares 99.9 % similarity with MDA-5, an inducible RNA helicase described recently. Ectopic expression of RH116 in HeLa-CD4 cells inhibited cell growth and cell proliferation but had no measurable effect on programmed cell death. RH116 presented steady state cytoplasmic localization and could translocate to the nucleus following HIV-1 infection. Moreover, the endogenous expression of RH116, at both the transcript and protein levels, was found to be considerably upregulated after infection. Overexpression of RH116 in HIV-1-infected HeLa-CD4 cells also resulted in a dramatic increase in the level of secreted viral p24 protein. This enhancement in virus replication did not stem from upregulated proviral DNA levels but correlated with increased unspliced and singly spliced viral mRNA transcripts. These findings implicate RH116 in the regulation of HIV-1 replication and point to an apoptosis-independent role for this novel helicase in inducing cell growth arrest.

[1]  A. Rice,et al.  Transient Induction of Cyclin T1 during Human Macrophage Differentiation Regulates Human Immunodeficiency Virus Type 1 Tat Transactivation Function , 2002, Journal of Virology.

[2]  G. Bahr,et al.  Clinical Tolerance and Immunologic Effects After Single or Repeated Administrations of the Synthetic Immunomodulator Murabutide in HIV‐1‐Infected Patients , 2002 .

[3]  F. Martinon,et al.  Overexpression of Helicard, a CARD-Containing Helicase Cleaved during Apoptosis, Accelerates DNA Degradation , 2002, Current Biology.

[4]  Wendy A Bickmore,et al.  Addressing protein localization within the nucleus , 2002, The EMBO journal.

[5]  E. Olson,et al.  Suppression of proliferation and cardiomyocyte hypertrophy by CHAMP, a cardiac-specific RNA helicase , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[6]  Paul B. Fisher,et al.  mda-5: An interferon-inducible putative RNA helicase with double-stranded RNA-dependent ATPase activity and melanoma growth-suppressive properties , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[7]  A. Capron,et al.  SS-56, a novel cellular target of autoantibody responses in Sjögren syndrome and systemic lupus erythematosus. , 2001, The Journal of clinical investigation.

[8]  G. Bahr,et al.  Selective Regulation of Human Immunodeficiency Virus-Infected CD4+ Lymphocytes by a Synthetic Immunomodulator Leads to Potent Virus Suppression In Vitro and in hu-PBL-SCID Mice , 2001, Journal of Virology.

[9]  A. Capron,et al.  Modulation of cellular and humoral immune responses to a multiepitopic HIV-1 DNA vaccine by interleukin-18 DNA immunization/viral protein boost. , 2001, Vaccine.

[10]  J. Angel Improving immune function and controlling viral replication in HIV-1-infected patients with immune-based therapies. , 2001, The AIDS reader.

[11]  C. Martínez-A,et al.  Cell-cycle regulation in immunity, tolerance and autoimmunity. , 2000, Immunology today.

[12]  G. Bahr,et al.  The Synthetic Immunomodulator Murabutide Controls Human Immunodeficiency Virus Type 1 Replication at Multiple Levels in Macrophages and Dendritic Cells , 2000, Journal of Virology.

[13]  F. Wong-Staal,et al.  Sam68, RNA helicase A and Tap cooperate in the post-transcriptional regulation of human immunodeficiency virus and type D retroviral mRNA , 2000, Oncogene.

[14]  M. Kazatchkine,et al.  High levels of drug-resistant human immunodeficiency virus variants in patients exhibiting increasing CD4+ T cell counts despite virologic failure of protease inhibitor-containing antiretroviral combination therapy. , 2000, The Journal of infectious diseases.

[15]  L. Schook,et al.  An RNA helicase, RHIV -1, induced by porcine reproductive and respiratory syndrome virus (PRRSV) is mapped on porcine chromosome 10q13. , 2000, Microbial pathogenesis.

[16]  Y. Cao,et al.  HIV-1 drug resistance in newly infected individuals. , 1999, JAMA.

[17]  G. Bahr,et al.  Interleukin-16 Inhibits Human Immunodeficiency Virus Type 1 Entry and Replication in Macrophages and in Dendritic Cells , 1999, Journal of Virology.

[18]  D. Hazuda,et al.  Host-cell positive transcription elongation factor b kinase activity is essential and limiting for HIV type 1 replication. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[19]  H. Worman,et al.  Hepatitis C Virus Core Protein Binds to a DEAD Box RNA Helicase* , 1999, The Journal of Biological Chemistry.

[20]  É. Cohen,et al.  Human Immunodeficiency Virus Type 1 (HIV-1) Vpr Functions as an Immediate-Early Protein during HIV-1 Infection , 1999, Journal of Virology.

[21]  Chi-Hung Lin,et al.  Hepatitis C Virus Core Protein Interacts with Cellular Putative RNA Helicase , 1999, Journal of Virology.

[22]  D. Rose,et al.  A role for RNA helicase A in post-transcriptional regulation of HIV type 1. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[23]  K. Roebuck,et al.  Human immunodeficiency virus type-1 transcription: role of the 5'-untranslated leader region (review). , 1998, International journal of molecular medicine.

[24]  D. Baltimore,et al.  HIV-1 Directly Kills CD4+ T Cells by a Fas-independent Mechanism , 1998, The Journal of experimental medicine.

[25]  D. Mosier,et al.  Apoptosis induced by HIV infection in H9 T cells is blocked by ICE-family protease inhibition but not by a Fas(CD95) antagonist. , 1996, Journal of immunology.

[26]  L. Chedid,et al.  Immunopharmacological activities and clinical development of muramyl peptides with particular emphasis on murabutide. , 1995, International journal of immunopharmacology.

[27]  G. Pavlakis,et al.  Splicing variability in HIV type 1 revealed by quantitative RNA polymerase chain reaction. , 1994, AIDS research and human retroviruses.

[28]  L. Chedid,et al.  Prophylactic and therapeutic effects of murabutide in OF1 mice infected with influenza A/H3N2 (A/Texas/1/77) virus. , 1988, Journal of biological response modifiers.

[29]  E. Lederer,et al.  Biological activity of a new synthetic muramyl peptide adjuvant devoid of pyrogenicity , 1982, Infection and immunity.

[30]  G. Bahr Non-specific immunotherapy of HIV-1 infection: potential use of the synthetic immunodulator murabutide. , 2003, The Journal of antimicrobial chemotherapy.

[31]  G. Bahr,et al.  Clinical tolerance and immunologic effects after single or repeated administrations of the synthetic immunomodulator murabutide in HIV-1-infected patients. , 2002, Journal of acquired immune deficiency syndromes.

[32]  Eckhard Jankowsky,et al.  The DExH/D protein family database , 2000, Nucleic Acids Res..

[33]  M. Lederman,et al.  Immune reconstitution in the first year of potent antiretroviral therapy and its relationship to virologic response. , 2000, The Journal of infectious diseases.

[34]  A. Capron,et al.  Interleukin-16 (IL-16) inhibits human immunodeficiency virus replication in cells from infected subjects, and serum IL-16 levels drop with disease progression. , 1999, The Journal of infectious diseases.

[35]  U. Stahl,et al.  The protein family of RNA helicases. , 1998, Critical reviews in biochemistry and molecular biology.

[36]  D O Morgan,et al.  Cyclin-dependent kinases: engines, clocks, and microprocessors. , 1997, Annual review of cell and developmental biology.

[37]  Gapped BLAST and PSI-BLAST: A new , 1997 .

[38]  J. Lifson,et al.  Quantitative competitive polymerase chain reaction for accurate quantitation of HIV DNA and RNA species. , 1993, BioTechniques.